FDA Fast Track Designation Granted to LYT-200 in Recurrent/Metastatic HNSCC
The galectin-9–targeted monoclonal antibody LYT-200 received FDA fast track designation for recurrent/metastatic head and neck squamous cell cancer.
The galectin-9–targeted monoclonal antibody LYT-200 received FDA fast track designation for recurrent/metastatic head and neck squamous cell cancer.
The Lancet’s Breast Cancer Commission, published on April 15, 2024, predicts that by 2040, the global incidence of new cases of breast cancer will be…
Peruse the current issue of The Lancet Oncology, a monthly journal covering international issues relevant to clinical cancer specialists worldwide
James Ferrara, MD, DSc, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, introduces a system for the risk…
Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.
The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.
This ESMO Webinar Series is available to all healthcare professionals working in Oncology.
The FDA has granted priority review to dostarlimab plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer.
Background The autologous anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple…
The FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR)–positive GEP-NETs.
Background The autologous anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple…